Vir Biotechnology
Vir Biotechnology Inc is a clinical-stage immunology and biopharmaceutical enterprise headquartered in San Francisco, California. The company focuses on the development of novel immunotherapies for the treatment and prevention of infectious diseases, including hepatitis B, influenza, and HIV. Its research pipeline leverages proprietary technology to identify and develop therapeutic agents that harness the immune system. Principal revenue is currently earned through strategic partnerships, research grants, and capital financing arrangements as clinical candidates progress through development. Vir Biotechnology Inc is publicly listed on the Nasdaq Stock Market.
3 of the funds FundTelligence covers report a position in Vir Biotechnology.
- Legal name
- VIR BIOTECHNOLOGY
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
Funds holding Vir Biotechnology
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.16 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.13 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)